43 studies found for:    Open Studies | "Arthritis, Psoriatic"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
Condition: Arthritis, Psoriatic
Intervention: Drug: Tofacitinib
2 Unknown  TIght COntrol of Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Intensive management or Tight control;   Drug: Standard management - Control group
3 Recruiting Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
Conditions: Psoriatic Arthritis;   Psoriasis
Intervention:
4 Recruiting Biologic Rheumatology Registry Across Canada
Conditions: Arthritis, Rheumatoid;   Spondylitis, Ankylosing;   Arthritis, Psoriatic
Intervention:
5 Recruiting To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis
Conditions: Psoriatic Arthritis;   Work Productivity
Intervention:
6 Not yet recruiting 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Biological: Secukinumab;   Biological: Placebo
7 Recruiting Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: Secukinumab
8 Recruiting Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention:
9 Recruiting Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo
10 Recruiting Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 30 mg;   Drug: Placebo
11 Recruiting Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Condition: Psoriatic Arthritis
Interventions: Drug: Tofacitinib 5 mg BID;   Drug: Tofacitinib 10 mg BID;   Drug: Adalimumab;   Drug: Placebo
12 Recruiting Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo
13 Recruiting Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: Open label H.P. Acthar Gel
14 Recruiting Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Condition: Psoriatic Arthritis
Interventions: Drug: Tofacitinib;   Other: Placebo
15 Not yet recruiting Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients
Condition: Psoriatic Arthritis
Interventions: Drug: Golimumab;   Drug: Methotrexate;   Drug: Placebo
16 Recruiting Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab (AIN457) in Patients of Active Psoriatic Arthritis (PsA).
Condition: Psoriatic Arthritis
Interventions: Biological: AIN457;   Drug: Placebo
17 Recruiting Psoriatic Arthritis Treat to Target vs. Usual Care
Condition: Psoriatic Arthritis (PsA)
Intervention: Other: Intensive Care
18 Recruiting PET/CT in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Radiation: FDG-PET/CT scan
19 Recruiting Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Abatacept;   Drug: Placebo matching with Abatacept
20 Recruiting The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Dietary Supplement: n-3PUFA;   Dietary Supplement: olive oil

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years